Cibus targets $200M annual rice royalties with expanded Latin America and India push while advancing biofragrance commercialization

Earnings Call Insights: Cibus, Inc. (CBUS) Q4 2025

MANAGEMENT VIEW

* Peter Beetham, Co-Founder, Interim CEO, President, and COO, stated that 2025 was a landmark year for Cibus driven by "technology leadership, commercialization progress, scale and regulatory momentum, all arriving at the same time." He highlighted 7 rice customers representing over $200 million in potential annual royalty opportunities, receipt of the first customer payment from the sustainable ingredients program, and a selection by the U.K. government as a technology partner. Beetham emphasized the company's transition to a "commercially-driven company with a powerful technology engine" and noted, "we have shifted to a commercially-driven company with a powerful technology engine."
* Beetham discussed the evolution of customer relationships, indicating that seed companies now seek "ongoing genomic editing relationships, not just one trait in one crop but the possibility of a broader engagement throughout their entire portfolio." He noted this opens opportunities for "outsourced gene editing" in high-growth markets including India, Asia, and Latin America.
* Regarding the rice program, Beetham said, "Our 7 rice customers across the United States and Latin America represent an incredible $200 million in potential annual royalty opportunity through our herbicide tolerant traits." He confirmed the company remains on track for initial market entry in Latin America in 2027, U.S. expansion in 2028, and India/Asia entry closer to 2030.
* The company executed a nonbinding LOI with Interoc for commercialization of herbicide tolerant rice in Latin America, with plans to expand into additional countries. Beetham confirmed edited material has been returned for registration work and expects to advance negotiations toward a definitive commercial agreement late in 2026.
* In sustainable ingredients, Beetham announced the first payments from the biofragrance program, with commercial scale production targeted "later this year" and a $20 million to $40 million annual royalty opportunity projected when fully commercialized.
* Gregory Gocal, Co-Founder and Chief Scientific Officer, highlighted an "order of magnitude improvement in our editing efficiency" in rice and noted the strategic use of AI and machine learning to accelerate trait development. Gocal explained, "Combined with our semi-automated workflows and robotic assistance, the trait machine process is becoming faster, more scalable and more efficient."
* Carlo Broos, Chief Financial Officer, stated, "Our cash and cash equivalents as of December 31, 2025, was $9.9 million. In January 2026, we raised $22.3 million in gross proceeds from a public offering." He noted, "we have reduced operating expenses by approximately $10 million across R&D and SG&A for the full year of 2025," and confirmed net loss was $31.9 million for the quarter.

OUTLOOK

* Beetham reiterated timelines for commercial launches: initial rice market entry in Latin America in 2027, U.S. expansion in 2028, and India/Asia closer to 2030. He also set expectations for field results from Latin America later in 2026 and noted progress on chemistry registrations supporting the 2027 launch.
* On the biofragrance program, Beetham stated, "we are formalizing our expanded partnership, targeting commercial scale production, and I believe we will be in a position to announce additional details on this program in the near term."
* Broos reported that existing cash is expected to fund operations into late third quarter 2026, and "reducing annual net cash usage to approximately $30 million or less in 2026" remains a goal.

FINANCIAL RESULTS

* Cash and cash equivalents as of December 31, 2025, were $9.9 million, with an additional $22.3 million raised in January 2026.
* Research and development expense for the quarter ended December 31, 2025, was $9.4 million, compared to $12.4 million in the year-ago period, attributed to cost reduction initiatives.
* Selling, general and administrative expense was $5.1 million for the quarter, compared to $6.8 million in the year-ago period.
* Royalty liability interest expense was $9.4 million for the quarter, up from $8.2 million in the year-ago period.
* Net loss was $31.9 million for the quarter ended December 31, 2025, compared to $25.8 million in the year-ago period.
* The company consolidated operations and reduced workforce to control cash usage, with a target to reduce annual net cash usage to $30 million or less in 2026.

Q&A

* Matthew Venezia, Alliance Global Partners: Asked about the EU NGT framework's impact on CapEx for canola WOSR. Beetham responded, "The EU regulatory progress is really a watershed moment... Europe is 100 million acres of greenfield opportunity... we've been developing a platform and a production system in Winter Oilseed Rape that is really efficient."
* Venezia asked about commercialization milestones in Latin America for rice. Beetham explained, "Our 7 partnerships in the Americas, the 5 in Latin America, the genetics that we're working on, and have worked on, are their best genetics, they're elite genetics... we've made those edits in the elite genetics."
* Laurence Alexander, Jefferies: Inquired about technology scale and royalty rates. Beetham stated, "we're targeting 5 million to 7 million acres in the Americas... building to that is going to take a couple of years through that process... once you're in that market, it is the stickiest business in the world."
* Alexander asked about scalability for fragrances. Beetham responded, "We've been working on a couple of fragrances to start with... we can scale that pretty quickly."
* Alex Hantman, Sidoti & Company: Asked about revenue timing and financing. Broos replied, "This is really timing... it's purely timing," and noted focus on near-term revenues in rice and fragrance.

SENTIMENT ANALYSIS

* Analysts focused on commercialization timelines, scalability, cash runway, and expansion opportunities, displaying a neutral to slightly positive tone. Questions were pragmatic about costs, revenue timing, and regulatory catalysts.
* Management's sentiment was confident and forward-looking, emphasizing momentum and scalability. Beetham's language included "coiled spring," "watershed moment," and "exciting part," reflecting optimism about regulatory and commercial progress.
* Compared to the previous quarter, management maintained a confident tone, but analysts in Q4 were slightly more focused on execution, cash management, and commercial scale.

QUARTER-OVER-QUARTER COMPARISON

* The transition from Q3 to Q4 saw the company advancing from early commercialization milestones to formalized customer engagements and initial royalty payments, particularly in rice and biofragrance.
* Guidance for rice and fragrance revenue timelines remained consistent, with continued emphasis on cost reduction and cash runway extension. The $200 million annual royalty target from rice was reiterated, with market entry timelines unchanged.
* Analysts in both quarters focused on commercialization progress, regulatory catalysts, and cash management, but Q4 featured deeper questions on scalability and partnership structures.
* Management's confidence grew as regulatory clarity increased and customer relationships deepened, with more specifics on pipeline and technical milestones.

RISKS AND CONCERNS

* Management acknowledged the importance of regulatory developments, especially in the EU, as a major determinant for commercial acceleration.
* Cash runway and the need for additional financing in late 2026 were discussed, with a focus on streamlining costs and pursuing near-term revenues.
* Analyst concerns centered on timing of revenue recognition, scalability of technology, and expansion of partnerships.

FINAL TAKEAWAY

Cibus management underscored a transformative year marked by strong regulatory momentum, customer engagement, and technical advances in gene editing. The company maintains a consistent focus on near-term revenue generation from rice and biofragrance programs, with a disciplined approach to cost control and capital allocation supporting a cash runway into late Q3 2026. Management projects significant royalty opportunities as commercial launches in Latin America, the U.S., and India approach, while regulatory progress in the EU and elsewhere is expected to unlock further growth and partnership potential.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/cbus/earnings/transcripts]

MORE ON CIBUS

* Cibus, Inc. (CBUS) Q4 2025 Earnings Call Transcript [https://seekingalpha.com/article/4883370-cibus-inc-cbus-q4-2025-earnings-call-transcript]
* Cibus' Agri-Bio Gamble - Technology Is Promising, Cash Is Limited, Execution Is Key [https://seekingalpha.com/article/4859141-cibus-agri-bio-gamble-technology-is-promising-cash-is-limited-execution-is-key]
* Quant snapshot: Micron, Babcock & Wilcox lead strong buys as Fold Holdings, Alvotech lag [https://seekingalpha.com/news/4563909-quant-snapshot-micron-babcock-wilcox-lead-strong-buys-as-fold-holdings-alvotech-lag]
* Cibus announces planned underwritten public offering of Class A shares; shares down [https://seekingalpha.com/news/4543809-cibus-announces-planned-underwritten-public-offering-of-class-a-shares-shares-down]
* Seeking Alpha’s Quant Rating on Cibus [https://seekingalpha.com/symbol/CBUS/ratings/quant-ratings]